Our proteomic microarray and immunoblot analyses showed that selinexor monotherapy had the ability to increase the level of γ-H2AX in both TP53-mutated and TP53 wild-type HGBCL-DH cells, consistent with the DNA damage-inducing activity of selinexor in acute leukemia cells. Here, TP53 is linked to acute leukemia.